Premium
Effects of Yangxue Qingnao Granules on chronic cerebral circulation insufficiency: a randomized, double‐blind, double‐dummy, controlled multicentre trial
Author(s) -
WU Chenghan,
LIAO Lianming,
YAN Xiaohua,
LI Meide,
WU Songying,
WANG Jinmin,
LIN Jushan,
LI Shiju,
GAO Lili,
DU Jian,
YANG Renmin
Publication year - 2013
Publication title -
psychogeriatrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.647
H-Index - 32
eISSN - 1479-8301
pISSN - 1346-3500
DOI - 10.1111/j.1479-8301.2012.00423.x
Subject(s) - nimodipine , medicine , placebo , adverse effect , randomized controlled trial , anesthesia , cerebral circulation , alternative medicine , pathology , calcium
Background: There is a great deal of interest in traditional Chinese medicine as a treatment for chronic cerebral circulation insufficiency (CCCI). In the present study, we evaluated the efficacy and safety of Yangxue Qingnao Granules (YXQNG) as a monotherapy in patients with CCCI. Methods: From July 2007 to May 2010, 273 patients with CCCI at nine centres in China were randomly assigned to receive either YXQNG with nimodipine placebo ( n = 140, 12 g/day) or nimodipine with YXQNG placebo ( n = 133, 30 mg/day) for 8 weeks. The primary end points after 8 weeks of treatment were changes from baseline in severity of headache, heavy‐headed feeling, dizziness and sleep disorder. Results: The mean baseline levels of headache, heavy‐headed feeling, dizziness and sleep disorder were comparable between the two groups. Both therapies significantly improved these symptoms after 8 weeks of treatment ( P < 0.001). Compared with nimodipine therapy, YXQNG resulted in similar reductions in these symptoms. No adverse effects were observed in the YXQNG group. Conclusions: These data demonstrate that YXQNG as a monotherapy were as effective as nimodipine monotherapy in improving the symptoms of CCCI. It is well‐tolerated and may have an important place in the management of this condition. Whether a combination of these two medicines will increase therapeutic efficacy deserves further clinical investigation.